Global Influenza Antiviral Drugs Market Research Report 2024(Status and Outlook)
Report Overview
This report provides a deep insight into the global Influenza Antiviral Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Influenza Antiviral Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Influenza Antiviral Drugs market in any manner.
Global Influenza Antiviral Drugs Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
GSK
Boehringer Ingelheim
Merck
Novartis
Beximco Pharmaceuticals
Pfizer
Roche
Johnson & Johnson
Sanofi
Cipla Limited
Natco Pharma
Seqirus
Adamas Pharmaceuticals, Inc.
Teva Pharmaceuticals
Daiichi Sankyo Company
Market Segmentation (by Type)
Oseltamivir
Zanamivir
Peramivir
Adamantanes
Others
Market Segmentation (by Application)
Hospitals
Clinics
Ambulatory Surgical Centers
Pharmacies
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Influenza Antiviral Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
This report provides a deep insight into the global Influenza Antiviral Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Influenza Antiviral Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Influenza Antiviral Drugs market in any manner.
Global Influenza Antiviral Drugs Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
GSK
Boehringer Ingelheim
Merck
Novartis
Beximco Pharmaceuticals
Pfizer
Roche
Johnson & Johnson
Sanofi
Cipla Limited
Natco Pharma
Seqirus
Adamas Pharmaceuticals, Inc.
Teva Pharmaceuticals
Daiichi Sankyo Company
Market Segmentation (by Type)
Oseltamivir
Zanamivir
Peramivir
Adamantanes
Others
Market Segmentation (by Application)
Hospitals
Clinics
Ambulatory Surgical Centers
Pharmacies
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Influenza Antiviral Drugs Market
- Overview of the regional outlook of the Influenza Antiviral Drugs Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Influenza Antiviral Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Influenza Antiviral Drugs
1.2 Key Market Segments
1.2.1 Influenza Antiviral Drugs Segment by Type
1.2.2 Influenza Antiviral Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 INFLUENZA ANTIVIRAL DRUGS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Influenza Antiviral Drugs Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Influenza Antiviral Drugs Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 INFLUENZA ANTIVIRAL DRUGS MARKET COMPETITIVE LANDSCAPE
3.1 Global Influenza Antiviral Drugs Sales by Manufacturers (2019-2024)
3.2 Global Influenza Antiviral Drugs Revenue Market Share by Manufacturers (2019-2024)
3.3 Influenza Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Influenza Antiviral Drugs Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Influenza Antiviral Drugs Sales Sites, Area Served, Product Type
3.6 Influenza Antiviral Drugs Market Competitive Situation and Trends
3.6.1 Influenza Antiviral Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Influenza Antiviral Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 INFLUENZA ANTIVIRAL DRUGS INDUSTRY CHAIN ANALYSIS
4.1 Influenza Antiviral Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF INFLUENZA ANTIVIRAL DRUGS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 INFLUENZA ANTIVIRAL DRUGS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Influenza Antiviral Drugs Sales Market Share by Type (2019-2024)
6.3 Global Influenza Antiviral Drugs Market Size Market Share by Type (2019-2024)
6.4 Global Influenza Antiviral Drugs Price by Type (2019-2024)
7 INFLUENZA ANTIVIRAL DRUGS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Influenza Antiviral Drugs Market Sales by Application (2019-2024)
7.3 Global Influenza Antiviral Drugs Market Size (M USD) by Application (2019-2024)
7.4 Global Influenza Antiviral Drugs Sales Growth Rate by Application (2019-2024)
8 INFLUENZA ANTIVIRAL DRUGS MARKET SEGMENTATION BY REGION
8.1 Global Influenza Antiviral Drugs Sales by Region
8.1.1 Global Influenza Antiviral Drugs Sales by Region
8.1.2 Global Influenza Antiviral Drugs Sales Market Share by Region
8.2 North America
8.2.1 North America Influenza Antiviral Drugs Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Influenza Antiviral Drugs Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Influenza Antiviral Drugs Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Influenza Antiviral Drugs Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Influenza Antiviral Drugs Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 GSK
9.1.1 GSK Influenza Antiviral Drugs Basic Information
9.1.2 GSK Influenza Antiviral Drugs Product Overview
9.1.3 GSK Influenza Antiviral Drugs Product Market Performance
9.1.4 GSK Business Overview
9.1.5 GSK Influenza Antiviral Drugs SWOT Analysis
9.1.6 GSK Recent Developments
9.2 Boehringer Ingelheim
9.2.1 Boehringer Ingelheim Influenza Antiviral Drugs Basic Information
9.2.2 Boehringer Ingelheim Influenza Antiviral Drugs Product Overview
9.2.3 Boehringer Ingelheim Influenza Antiviral Drugs Product Market Performance
9.2.4 Boehringer Ingelheim Business Overview
9.2.5 Boehringer Ingelheim Influenza Antiviral Drugs SWOT Analysis
9.2.6 Boehringer Ingelheim Recent Developments
9.3 Merck
9.3.1 Merck Influenza Antiviral Drugs Basic Information
9.3.2 Merck Influenza Antiviral Drugs Product Overview
9.3.3 Merck Influenza Antiviral Drugs Product Market Performance
9.3.4 Merck Influenza Antiviral Drugs SWOT Analysis
9.3.5 Merck Business Overview
9.3.6 Merck Recent Developments
9.4 Novartis
9.4.1 Novartis Influenza Antiviral Drugs Basic Information
9.4.2 Novartis Influenza Antiviral Drugs Product Overview
9.4.3 Novartis Influenza Antiviral Drugs Product Market Performance
9.4.4 Novartis Business Overview
9.4.5 Novartis Recent Developments
9.5 Beximco Pharmaceuticals
9.5.1 Beximco Pharmaceuticals Influenza Antiviral Drugs Basic Information
9.5.2 Beximco Pharmaceuticals Influenza Antiviral Drugs Product Overview
9.5.3 Beximco Pharmaceuticals Influenza Antiviral Drugs Product Market Performance
9.5.4 Beximco Pharmaceuticals Business Overview
9.5.5 Beximco Pharmaceuticals Recent Developments
9.6 Pfizer
9.6.1 Pfizer Influenza Antiviral Drugs Basic Information
9.6.2 Pfizer Influenza Antiviral Drugs Product Overview
9.6.3 Pfizer Influenza Antiviral Drugs Product Market Performance
9.6.4 Pfizer Business Overview
9.6.5 Pfizer Recent Developments
9.7 Roche
9.7.1 Roche Influenza Antiviral Drugs Basic Information
9.7.2 Roche Influenza Antiviral Drugs Product Overview
9.7.3 Roche Influenza Antiviral Drugs Product Market Performance
9.7.4 Roche Business Overview
9.7.5 Roche Recent Developments
9.8 Johnson and Johnson
9.8.1 Johnson and Johnson Influenza Antiviral Drugs Basic Information
9.8.2 Johnson and Johnson Influenza Antiviral Drugs Product Overview
9.8.3 Johnson and Johnson Influenza Antiviral Drugs Product Market Performance
9.8.4 Johnson and Johnson Business Overview
9.8.5 Johnson and Johnson Recent Developments
9.9 Sanofi
9.9.1 Sanofi Influenza Antiviral Drugs Basic Information
9.9.2 Sanofi Influenza Antiviral Drugs Product Overview
9.9.3 Sanofi Influenza Antiviral Drugs Product Market Performance
9.9.4 Sanofi Business Overview
9.9.5 Sanofi Recent Developments
9.10 Cipla Limited
9.10.1 Cipla Limited Influenza Antiviral Drugs Basic Information
9.10.2 Cipla Limited Influenza Antiviral Drugs Product Overview
9.10.3 Cipla Limited Influenza Antiviral Drugs Product Market Performance
9.10.4 Cipla Limited Business Overview
9.10.5 Cipla Limited Recent Developments
9.11 Natco Pharma
9.11.1 Natco Pharma Influenza Antiviral Drugs Basic Information
9.11.2 Natco Pharma Influenza Antiviral Drugs Product Overview
9.11.3 Natco Pharma Influenza Antiviral Drugs Product Market Performance
9.11.4 Natco Pharma Business Overview
9.11.5 Natco Pharma Recent Developments
9.12 Seqirus
9.12.1 Seqirus Influenza Antiviral Drugs Basic Information
9.12.2 Seqirus Influenza Antiviral Drugs Product Overview
9.12.3 Seqirus Influenza Antiviral Drugs Product Market Performance
9.12.4 Seqirus Business Overview
9.12.5 Seqirus Recent Developments
9.13 Adamas Pharmaceuticals, Inc.
9.13.1 Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Basic Information
9.13.2 Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Product Overview
9.13.3 Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Product Market Performance
9.13.4 Adamas Pharmaceuticals, Inc. Business Overview
9.13.5 Adamas Pharmaceuticals, Inc. Recent Developments
9.14 Teva Pharmaceuticals
9.14.1 Teva Pharmaceuticals Influenza Antiviral Drugs Basic Information
9.14.2 Teva Pharmaceuticals Influenza Antiviral Drugs Product Overview
9.14.3 Teva Pharmaceuticals Influenza Antiviral Drugs Product Market Performance
9.14.4 Teva Pharmaceuticals Business Overview
9.14.5 Teva Pharmaceuticals Recent Developments
9.15 Daiichi Sankyo Company
9.15.1 Daiichi Sankyo Company Influenza Antiviral Drugs Basic Information
9.15.2 Daiichi Sankyo Company Influenza Antiviral Drugs Product Overview
9.15.3 Daiichi Sankyo Company Influenza Antiviral Drugs Product Market Performance
9.15.4 Daiichi Sankyo Company Business Overview
9.15.5 Daiichi Sankyo Company Recent Developments
10 INFLUENZA ANTIVIRAL DRUGS MARKET FORECAST BY REGION
10.1 Global Influenza Antiviral Drugs Market Size Forecast
10.2 Global Influenza Antiviral Drugs Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Influenza Antiviral Drugs Market Size Forecast by Country
10.2.3 Asia Pacific Influenza Antiviral Drugs Market Size Forecast by Region
10.2.4 South America Influenza Antiviral Drugs Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Influenza Antiviral Drugs by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Influenza Antiviral Drugs Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Influenza Antiviral Drugs by Type (2025-2030)
11.1.2 Global Influenza Antiviral Drugs Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Influenza Antiviral Drugs by Type (2025-2030)
11.2 Global Influenza Antiviral Drugs Market Forecast by Application (2025-2030)
11.2.1 Global Influenza Antiviral Drugs Sales (K Units) Forecast by Application
11.2.2 Global Influenza Antiviral Drugs Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Influenza Antiviral Drugs
1.2 Key Market Segments
1.2.1 Influenza Antiviral Drugs Segment by Type
1.2.2 Influenza Antiviral Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 INFLUENZA ANTIVIRAL DRUGS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Influenza Antiviral Drugs Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Influenza Antiviral Drugs Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 INFLUENZA ANTIVIRAL DRUGS MARKET COMPETITIVE LANDSCAPE
3.1 Global Influenza Antiviral Drugs Sales by Manufacturers (2019-2024)
3.2 Global Influenza Antiviral Drugs Revenue Market Share by Manufacturers (2019-2024)
3.3 Influenza Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Influenza Antiviral Drugs Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Influenza Antiviral Drugs Sales Sites, Area Served, Product Type
3.6 Influenza Antiviral Drugs Market Competitive Situation and Trends
3.6.1 Influenza Antiviral Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Influenza Antiviral Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 INFLUENZA ANTIVIRAL DRUGS INDUSTRY CHAIN ANALYSIS
4.1 Influenza Antiviral Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF INFLUENZA ANTIVIRAL DRUGS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 INFLUENZA ANTIVIRAL DRUGS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Influenza Antiviral Drugs Sales Market Share by Type (2019-2024)
6.3 Global Influenza Antiviral Drugs Market Size Market Share by Type (2019-2024)
6.4 Global Influenza Antiviral Drugs Price by Type (2019-2024)
7 INFLUENZA ANTIVIRAL DRUGS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Influenza Antiviral Drugs Market Sales by Application (2019-2024)
7.3 Global Influenza Antiviral Drugs Market Size (M USD) by Application (2019-2024)
7.4 Global Influenza Antiviral Drugs Sales Growth Rate by Application (2019-2024)
8 INFLUENZA ANTIVIRAL DRUGS MARKET SEGMENTATION BY REGION
8.1 Global Influenza Antiviral Drugs Sales by Region
8.1.1 Global Influenza Antiviral Drugs Sales by Region
8.1.2 Global Influenza Antiviral Drugs Sales Market Share by Region
8.2 North America
8.2.1 North America Influenza Antiviral Drugs Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Influenza Antiviral Drugs Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Influenza Antiviral Drugs Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Influenza Antiviral Drugs Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Influenza Antiviral Drugs Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 GSK
9.1.1 GSK Influenza Antiviral Drugs Basic Information
9.1.2 GSK Influenza Antiviral Drugs Product Overview
9.1.3 GSK Influenza Antiviral Drugs Product Market Performance
9.1.4 GSK Business Overview
9.1.5 GSK Influenza Antiviral Drugs SWOT Analysis
9.1.6 GSK Recent Developments
9.2 Boehringer Ingelheim
9.2.1 Boehringer Ingelheim Influenza Antiviral Drugs Basic Information
9.2.2 Boehringer Ingelheim Influenza Antiviral Drugs Product Overview
9.2.3 Boehringer Ingelheim Influenza Antiviral Drugs Product Market Performance
9.2.4 Boehringer Ingelheim Business Overview
9.2.5 Boehringer Ingelheim Influenza Antiviral Drugs SWOT Analysis
9.2.6 Boehringer Ingelheim Recent Developments
9.3 Merck
9.3.1 Merck Influenza Antiviral Drugs Basic Information
9.3.2 Merck Influenza Antiviral Drugs Product Overview
9.3.3 Merck Influenza Antiviral Drugs Product Market Performance
9.3.4 Merck Influenza Antiviral Drugs SWOT Analysis
9.3.5 Merck Business Overview
9.3.6 Merck Recent Developments
9.4 Novartis
9.4.1 Novartis Influenza Antiviral Drugs Basic Information
9.4.2 Novartis Influenza Antiviral Drugs Product Overview
9.4.3 Novartis Influenza Antiviral Drugs Product Market Performance
9.4.4 Novartis Business Overview
9.4.5 Novartis Recent Developments
9.5 Beximco Pharmaceuticals
9.5.1 Beximco Pharmaceuticals Influenza Antiviral Drugs Basic Information
9.5.2 Beximco Pharmaceuticals Influenza Antiviral Drugs Product Overview
9.5.3 Beximco Pharmaceuticals Influenza Antiviral Drugs Product Market Performance
9.5.4 Beximco Pharmaceuticals Business Overview
9.5.5 Beximco Pharmaceuticals Recent Developments
9.6 Pfizer
9.6.1 Pfizer Influenza Antiviral Drugs Basic Information
9.6.2 Pfizer Influenza Antiviral Drugs Product Overview
9.6.3 Pfizer Influenza Antiviral Drugs Product Market Performance
9.6.4 Pfizer Business Overview
9.6.5 Pfizer Recent Developments
9.7 Roche
9.7.1 Roche Influenza Antiviral Drugs Basic Information
9.7.2 Roche Influenza Antiviral Drugs Product Overview
9.7.3 Roche Influenza Antiviral Drugs Product Market Performance
9.7.4 Roche Business Overview
9.7.5 Roche Recent Developments
9.8 Johnson and Johnson
9.8.1 Johnson and Johnson Influenza Antiviral Drugs Basic Information
9.8.2 Johnson and Johnson Influenza Antiviral Drugs Product Overview
9.8.3 Johnson and Johnson Influenza Antiviral Drugs Product Market Performance
9.8.4 Johnson and Johnson Business Overview
9.8.5 Johnson and Johnson Recent Developments
9.9 Sanofi
9.9.1 Sanofi Influenza Antiviral Drugs Basic Information
9.9.2 Sanofi Influenza Antiviral Drugs Product Overview
9.9.3 Sanofi Influenza Antiviral Drugs Product Market Performance
9.9.4 Sanofi Business Overview
9.9.5 Sanofi Recent Developments
9.10 Cipla Limited
9.10.1 Cipla Limited Influenza Antiviral Drugs Basic Information
9.10.2 Cipla Limited Influenza Antiviral Drugs Product Overview
9.10.3 Cipla Limited Influenza Antiviral Drugs Product Market Performance
9.10.4 Cipla Limited Business Overview
9.10.5 Cipla Limited Recent Developments
9.11 Natco Pharma
9.11.1 Natco Pharma Influenza Antiviral Drugs Basic Information
9.11.2 Natco Pharma Influenza Antiviral Drugs Product Overview
9.11.3 Natco Pharma Influenza Antiviral Drugs Product Market Performance
9.11.4 Natco Pharma Business Overview
9.11.5 Natco Pharma Recent Developments
9.12 Seqirus
9.12.1 Seqirus Influenza Antiviral Drugs Basic Information
9.12.2 Seqirus Influenza Antiviral Drugs Product Overview
9.12.3 Seqirus Influenza Antiviral Drugs Product Market Performance
9.12.4 Seqirus Business Overview
9.12.5 Seqirus Recent Developments
9.13 Adamas Pharmaceuticals, Inc.
9.13.1 Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Basic Information
9.13.2 Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Product Overview
9.13.3 Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Product Market Performance
9.13.4 Adamas Pharmaceuticals, Inc. Business Overview
9.13.5 Adamas Pharmaceuticals, Inc. Recent Developments
9.14 Teva Pharmaceuticals
9.14.1 Teva Pharmaceuticals Influenza Antiviral Drugs Basic Information
9.14.2 Teva Pharmaceuticals Influenza Antiviral Drugs Product Overview
9.14.3 Teva Pharmaceuticals Influenza Antiviral Drugs Product Market Performance
9.14.4 Teva Pharmaceuticals Business Overview
9.14.5 Teva Pharmaceuticals Recent Developments
9.15 Daiichi Sankyo Company
9.15.1 Daiichi Sankyo Company Influenza Antiviral Drugs Basic Information
9.15.2 Daiichi Sankyo Company Influenza Antiviral Drugs Product Overview
9.15.3 Daiichi Sankyo Company Influenza Antiviral Drugs Product Market Performance
9.15.4 Daiichi Sankyo Company Business Overview
9.15.5 Daiichi Sankyo Company Recent Developments
10 INFLUENZA ANTIVIRAL DRUGS MARKET FORECAST BY REGION
10.1 Global Influenza Antiviral Drugs Market Size Forecast
10.2 Global Influenza Antiviral Drugs Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Influenza Antiviral Drugs Market Size Forecast by Country
10.2.3 Asia Pacific Influenza Antiviral Drugs Market Size Forecast by Region
10.2.4 South America Influenza Antiviral Drugs Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Influenza Antiviral Drugs by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Influenza Antiviral Drugs Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Influenza Antiviral Drugs by Type (2025-2030)
11.1.2 Global Influenza Antiviral Drugs Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Influenza Antiviral Drugs by Type (2025-2030)
11.2 Global Influenza Antiviral Drugs Market Forecast by Application (2025-2030)
11.2.1 Global Influenza Antiviral Drugs Sales (K Units) Forecast by Application
11.2.2 Global Influenza Antiviral Drugs Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Influenza Antiviral Drugs Market Size Comparison by Region (M USD)
Table 5. Global Influenza Antiviral Drugs Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Influenza Antiviral Drugs Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Influenza Antiviral Drugs Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Influenza Antiviral Drugs Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Antiviral Drugs as of 2022)
Table 10. Global Market Influenza Antiviral Drugs Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Influenza Antiviral Drugs Sales Sites and Area Served
Table 12. Manufacturers Influenza Antiviral Drugs Product Type
Table 13. Global Influenza Antiviral Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Influenza Antiviral Drugs
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Influenza Antiviral Drugs Market Challenges
Table 22. Global Influenza Antiviral Drugs Sales by Type (K Units)
Table 23. Global Influenza Antiviral Drugs Market Size by Type (M USD)
Table 24. Global Influenza Antiviral Drugs Sales (K Units) by Type (2019-2024)
Table 25. Global Influenza Antiviral Drugs Sales Market Share by Type (2019-2024)
Table 26. Global Influenza Antiviral Drugs Market Size (M USD) by Type (2019-2024)
Table 27. Global Influenza Antiviral Drugs Market Size Share by Type (2019-2024)
Table 28. Global Influenza Antiviral Drugs Price (USD/Unit) by Type (2019-2024)
Table 29. Global Influenza Antiviral Drugs Sales (K Units) by Application
Table 30. Global Influenza Antiviral Drugs Market Size by Application
Table 31. Global Influenza Antiviral Drugs Sales by Application (2019-2024) & (K Units)
Table 32. Global Influenza Antiviral Drugs Sales Market Share by Application (2019-2024)
Table 33. Global Influenza Antiviral Drugs Sales by Application (2019-2024) & (M USD)
Table 34. Global Influenza Antiviral Drugs Market Share by Application (2019-2024)
Table 35. Global Influenza Antiviral Drugs Sales Growth Rate by Application (2019-2024)
Table 36. Global Influenza Antiviral Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Global Influenza Antiviral Drugs Sales Market Share by Region (2019-2024)
Table 38. North America Influenza Antiviral Drugs Sales by Country (2019-2024) & (K Units)
Table 39. Europe Influenza Antiviral Drugs Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Influenza Antiviral Drugs Sales by Region (2019-2024) & (K Units)
Table 41. South America Influenza Antiviral Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Influenza Antiviral Drugs Sales by Region (2019-2024) & (K Units)
Table 43. GSK Influenza Antiviral Drugs Basic Information
Table 44. GSK Influenza Antiviral Drugs Product Overview
Table 45. GSK Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. GSK Business Overview
Table 47. GSK Influenza Antiviral Drugs SWOT Analysis
Table 48. GSK Recent Developments
Table 49. Boehringer Ingelheim Influenza Antiviral Drugs Basic Information
Table 50. Boehringer Ingelheim Influenza Antiviral Drugs Product Overview
Table 51. Boehringer Ingelheim Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Boehringer Ingelheim Business Overview
Table 53. Boehringer Ingelheim Influenza Antiviral Drugs SWOT Analysis
Table 54. Boehringer Ingelheim Recent Developments
Table 55. Merck Influenza Antiviral Drugs Basic Information
Table 56. Merck Influenza Antiviral Drugs Product Overview
Table 57. Merck Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Merck Influenza Antiviral Drugs SWOT Analysis
Table 59. Merck Business Overview
Table 60. Merck Recent Developments
Table 61. Novartis Influenza Antiviral Drugs Basic Information
Table 62. Novartis Influenza Antiviral Drugs Product Overview
Table 63. Novartis Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Novartis Business Overview
Table 65. Novartis Recent Developments
Table 66. Beximco Pharmaceuticals Influenza Antiviral Drugs Basic Information
Table 67. Beximco Pharmaceuticals Influenza Antiviral Drugs Product Overview
Table 68. Beximco Pharmaceuticals Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Beximco Pharmaceuticals Business Overview
Table 70. Beximco Pharmaceuticals Recent Developments
Table 71. Pfizer Influenza Antiviral Drugs Basic Information
Table 72. Pfizer Influenza Antiviral Drugs Product Overview
Table 73. Pfizer Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Pfizer Business Overview
Table 75. Pfizer Recent Developments
Table 76. Roche Influenza Antiviral Drugs Basic Information
Table 77. Roche Influenza Antiviral Drugs Product Overview
Table 78. Roche Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Roche Business Overview
Table 80. Roche Recent Developments
Table 81. Johnson and Johnson Influenza Antiviral Drugs Basic Information
Table 82. Johnson and Johnson Influenza Antiviral Drugs Product Overview
Table 83. Johnson and Johnson Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Johnson and Johnson Business Overview
Table 85. Johnson and Johnson Recent Developments
Table 86. Sanofi Influenza Antiviral Drugs Basic Information
Table 87. Sanofi Influenza Antiviral Drugs Product Overview
Table 88. Sanofi Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Sanofi Business Overview
Table 90. Sanofi Recent Developments
Table 91. Cipla Limited Influenza Antiviral Drugs Basic Information
Table 92. Cipla Limited Influenza Antiviral Drugs Product Overview
Table 93. Cipla Limited Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Cipla Limited Business Overview
Table 95. Cipla Limited Recent Developments
Table 96. Natco Pharma Influenza Antiviral Drugs Basic Information
Table 97. Natco Pharma Influenza Antiviral Drugs Product Overview
Table 98. Natco Pharma Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Natco Pharma Business Overview
Table 100. Natco Pharma Recent Developments
Table 101. Seqirus Influenza Antiviral Drugs Basic Information
Table 102. Seqirus Influenza Antiviral Drugs Product Overview
Table 103. Seqirus Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Seqirus Business Overview
Table 105. Seqirus Recent Developments
Table 106. Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Basic Information
Table 107. Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Product Overview
Table 108. Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Adamas Pharmaceuticals, Inc. Business Overview
Table 110. Adamas Pharmaceuticals, Inc. Recent Developments
Table 111. Teva Pharmaceuticals Influenza Antiviral Drugs Basic Information
Table 112. Teva Pharmaceuticals Influenza Antiviral Drugs Product Overview
Table 113. Teva Pharmaceuticals Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Teva Pharmaceuticals Business Overview
Table 115. Teva Pharmaceuticals Recent Developments
Table 116. Daiichi Sankyo Company Influenza Antiviral Drugs Basic Information
Table 117. Daiichi Sankyo Company Influenza Antiviral Drugs Product Overview
Table 118. Daiichi Sankyo Company Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Daiichi Sankyo Company Business Overview
Table 120. Daiichi Sankyo Company Recent Developments
Table 121. Global Influenza Antiviral Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 122. Global Influenza Antiviral Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 123. North America Influenza Antiviral Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 124. North America Influenza Antiviral Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 125. Europe Influenza Antiviral Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 126. Europe Influenza Antiviral Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 127. Asia Pacific Influenza Antiviral Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 128. Asia Pacific Influenza Antiviral Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 129. South America Influenza Antiviral Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 130. South America Influenza Antiviral Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 131. Middle East and Africa Influenza Antiviral Drugs Consumption Forecast by Country (2025-2030) & (Units)
Table 132. Middle East and Africa Influenza Antiviral Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 133. Global Influenza Antiviral Drugs Sales Forecast by Type (2025-2030) & (K Units)
Table 134. Global Influenza Antiviral Drugs Market Size Forecast by Type (2025-2030) & (M USD)
Table 135. Global Influenza Antiviral Drugs Price Forecast by Type (2025-2030) & (USD/Unit)
Table 136. Global Influenza Antiviral Drugs Sales (K Units) Forecast by Application (2025-2030)
Table 137. Global Influenza Antiviral Drugs Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Influenza Antiviral Drugs Market Size Comparison by Region (M USD)
Table 5. Global Influenza Antiviral Drugs Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Influenza Antiviral Drugs Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Influenza Antiviral Drugs Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Influenza Antiviral Drugs Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Antiviral Drugs as of 2022)
Table 10. Global Market Influenza Antiviral Drugs Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Influenza Antiviral Drugs Sales Sites and Area Served
Table 12. Manufacturers Influenza Antiviral Drugs Product Type
Table 13. Global Influenza Antiviral Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Influenza Antiviral Drugs
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Influenza Antiviral Drugs Market Challenges
Table 22. Global Influenza Antiviral Drugs Sales by Type (K Units)
Table 23. Global Influenza Antiviral Drugs Market Size by Type (M USD)
Table 24. Global Influenza Antiviral Drugs Sales (K Units) by Type (2019-2024)
Table 25. Global Influenza Antiviral Drugs Sales Market Share by Type (2019-2024)
Table 26. Global Influenza Antiviral Drugs Market Size (M USD) by Type (2019-2024)
Table 27. Global Influenza Antiviral Drugs Market Size Share by Type (2019-2024)
Table 28. Global Influenza Antiviral Drugs Price (USD/Unit) by Type (2019-2024)
Table 29. Global Influenza Antiviral Drugs Sales (K Units) by Application
Table 30. Global Influenza Antiviral Drugs Market Size by Application
Table 31. Global Influenza Antiviral Drugs Sales by Application (2019-2024) & (K Units)
Table 32. Global Influenza Antiviral Drugs Sales Market Share by Application (2019-2024)
Table 33. Global Influenza Antiviral Drugs Sales by Application (2019-2024) & (M USD)
Table 34. Global Influenza Antiviral Drugs Market Share by Application (2019-2024)
Table 35. Global Influenza Antiviral Drugs Sales Growth Rate by Application (2019-2024)
Table 36. Global Influenza Antiviral Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Global Influenza Antiviral Drugs Sales Market Share by Region (2019-2024)
Table 38. North America Influenza Antiviral Drugs Sales by Country (2019-2024) & (K Units)
Table 39. Europe Influenza Antiviral Drugs Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Influenza Antiviral Drugs Sales by Region (2019-2024) & (K Units)
Table 41. South America Influenza Antiviral Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Influenza Antiviral Drugs Sales by Region (2019-2024) & (K Units)
Table 43. GSK Influenza Antiviral Drugs Basic Information
Table 44. GSK Influenza Antiviral Drugs Product Overview
Table 45. GSK Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. GSK Business Overview
Table 47. GSK Influenza Antiviral Drugs SWOT Analysis
Table 48. GSK Recent Developments
Table 49. Boehringer Ingelheim Influenza Antiviral Drugs Basic Information
Table 50. Boehringer Ingelheim Influenza Antiviral Drugs Product Overview
Table 51. Boehringer Ingelheim Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Boehringer Ingelheim Business Overview
Table 53. Boehringer Ingelheim Influenza Antiviral Drugs SWOT Analysis
Table 54. Boehringer Ingelheim Recent Developments
Table 55. Merck Influenza Antiviral Drugs Basic Information
Table 56. Merck Influenza Antiviral Drugs Product Overview
Table 57. Merck Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Merck Influenza Antiviral Drugs SWOT Analysis
Table 59. Merck Business Overview
Table 60. Merck Recent Developments
Table 61. Novartis Influenza Antiviral Drugs Basic Information
Table 62. Novartis Influenza Antiviral Drugs Product Overview
Table 63. Novartis Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Novartis Business Overview
Table 65. Novartis Recent Developments
Table 66. Beximco Pharmaceuticals Influenza Antiviral Drugs Basic Information
Table 67. Beximco Pharmaceuticals Influenza Antiviral Drugs Product Overview
Table 68. Beximco Pharmaceuticals Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Beximco Pharmaceuticals Business Overview
Table 70. Beximco Pharmaceuticals Recent Developments
Table 71. Pfizer Influenza Antiviral Drugs Basic Information
Table 72. Pfizer Influenza Antiviral Drugs Product Overview
Table 73. Pfizer Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Pfizer Business Overview
Table 75. Pfizer Recent Developments
Table 76. Roche Influenza Antiviral Drugs Basic Information
Table 77. Roche Influenza Antiviral Drugs Product Overview
Table 78. Roche Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Roche Business Overview
Table 80. Roche Recent Developments
Table 81. Johnson and Johnson Influenza Antiviral Drugs Basic Information
Table 82. Johnson and Johnson Influenza Antiviral Drugs Product Overview
Table 83. Johnson and Johnson Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Johnson and Johnson Business Overview
Table 85. Johnson and Johnson Recent Developments
Table 86. Sanofi Influenza Antiviral Drugs Basic Information
Table 87. Sanofi Influenza Antiviral Drugs Product Overview
Table 88. Sanofi Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Sanofi Business Overview
Table 90. Sanofi Recent Developments
Table 91. Cipla Limited Influenza Antiviral Drugs Basic Information
Table 92. Cipla Limited Influenza Antiviral Drugs Product Overview
Table 93. Cipla Limited Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Cipla Limited Business Overview
Table 95. Cipla Limited Recent Developments
Table 96. Natco Pharma Influenza Antiviral Drugs Basic Information
Table 97. Natco Pharma Influenza Antiviral Drugs Product Overview
Table 98. Natco Pharma Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Natco Pharma Business Overview
Table 100. Natco Pharma Recent Developments
Table 101. Seqirus Influenza Antiviral Drugs Basic Information
Table 102. Seqirus Influenza Antiviral Drugs Product Overview
Table 103. Seqirus Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Seqirus Business Overview
Table 105. Seqirus Recent Developments
Table 106. Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Basic Information
Table 107. Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Product Overview
Table 108. Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Adamas Pharmaceuticals, Inc. Business Overview
Table 110. Adamas Pharmaceuticals, Inc. Recent Developments
Table 111. Teva Pharmaceuticals Influenza Antiviral Drugs Basic Information
Table 112. Teva Pharmaceuticals Influenza Antiviral Drugs Product Overview
Table 113. Teva Pharmaceuticals Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Teva Pharmaceuticals Business Overview
Table 115. Teva Pharmaceuticals Recent Developments
Table 116. Daiichi Sankyo Company Influenza Antiviral Drugs Basic Information
Table 117. Daiichi Sankyo Company Influenza Antiviral Drugs Product Overview
Table 118. Daiichi Sankyo Company Influenza Antiviral Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Daiichi Sankyo Company Business Overview
Table 120. Daiichi Sankyo Company Recent Developments
Table 121. Global Influenza Antiviral Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 122. Global Influenza Antiviral Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 123. North America Influenza Antiviral Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 124. North America Influenza Antiviral Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 125. Europe Influenza Antiviral Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 126. Europe Influenza Antiviral Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 127. Asia Pacific Influenza Antiviral Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 128. Asia Pacific Influenza Antiviral Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 129. South America Influenza Antiviral Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 130. South America Influenza Antiviral Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 131. Middle East and Africa Influenza Antiviral Drugs Consumption Forecast by Country (2025-2030) & (Units)
Table 132. Middle East and Africa Influenza Antiviral Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 133. Global Influenza Antiviral Drugs Sales Forecast by Type (2025-2030) & (K Units)
Table 134. Global Influenza Antiviral Drugs Market Size Forecast by Type (2025-2030) & (M USD)
Table 135. Global Influenza Antiviral Drugs Price Forecast by Type (2025-2030) & (USD/Unit)
Table 136. Global Influenza Antiviral Drugs Sales (K Units) Forecast by Application (2025-2030)
Table 137. Global Influenza Antiviral Drugs Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Influenza Antiviral Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Influenza Antiviral Drugs Market Size (M USD), 2019-2030
Figure 5. Global Influenza Antiviral Drugs Market Size (M USD) (2019-2030)
Figure 6. Global Influenza Antiviral Drugs Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Influenza Antiviral Drugs Market Size by Country (M USD)
Figure 11. Influenza Antiviral Drugs Sales Share by Manufacturers in 2023
Figure 12. Global Influenza Antiviral Drugs Revenue Share by Manufacturers in 2023
Figure 13. Influenza Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Influenza Antiviral Drugs Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Influenza Antiviral Drugs Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Influenza Antiviral Drugs Market Share by Type
Figure 18. Sales Market Share of Influenza Antiviral Drugs by Type (2019-2024)
Figure 19. Sales Market Share of Influenza Antiviral Drugs by Type in 2023
Figure 20. Market Size Share of Influenza Antiviral Drugs by Type (2019-2024)
Figure 21. Market Size Market Share of Influenza Antiviral Drugs by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Influenza Antiviral Drugs Market Share by Application
Figure 24. Global Influenza Antiviral Drugs Sales Market Share by Application (2019-2024)
Figure 25. Global Influenza Antiviral Drugs Sales Market Share by Application in 2023
Figure 26. Global Influenza Antiviral Drugs Market Share by Application (2019-2024)
Figure 27. Global Influenza Antiviral Drugs Market Share by Application in 2023
Figure 28. Global Influenza Antiviral Drugs Sales Growth Rate by Application (2019-2024)
Figure 29. Global Influenza Antiviral Drugs Sales Market Share by Region (2019-2024)
Figure 30. North America Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Influenza Antiviral Drugs Sales Market Share by Country in 2023
Figure 32. U.S. Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Influenza Antiviral Drugs Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Influenza Antiviral Drugs Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Influenza Antiviral Drugs Sales Market Share by Country in 2023
Figure 37. Germany Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Influenza Antiviral Drugs Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Influenza Antiviral Drugs Sales Market Share by Region in 2023
Figure 44. China Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Influenza Antiviral Drugs Sales and Growth Rate (K Units)
Figure 50. South America Influenza Antiviral Drugs Sales Market Share by Country in 2023
Figure 51. Brazil Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Influenza Antiviral Drugs Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Influenza Antiviral Drugs Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Influenza Antiviral Drugs Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Influenza Antiviral Drugs Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Influenza Antiviral Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Influenza Antiviral Drugs Market Share Forecast by Type (2025-2030)
Figure 65. Global Influenza Antiviral Drugs Sales Forecast by Application (2025-2030)
Figure 66. Global Influenza Antiviral Drugs Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Influenza Antiviral Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Influenza Antiviral Drugs Market Size (M USD), 2019-2030
Figure 5. Global Influenza Antiviral Drugs Market Size (M USD) (2019-2030)
Figure 6. Global Influenza Antiviral Drugs Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Influenza Antiviral Drugs Market Size by Country (M USD)
Figure 11. Influenza Antiviral Drugs Sales Share by Manufacturers in 2023
Figure 12. Global Influenza Antiviral Drugs Revenue Share by Manufacturers in 2023
Figure 13. Influenza Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Influenza Antiviral Drugs Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Influenza Antiviral Drugs Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Influenza Antiviral Drugs Market Share by Type
Figure 18. Sales Market Share of Influenza Antiviral Drugs by Type (2019-2024)
Figure 19. Sales Market Share of Influenza Antiviral Drugs by Type in 2023
Figure 20. Market Size Share of Influenza Antiviral Drugs by Type (2019-2024)
Figure 21. Market Size Market Share of Influenza Antiviral Drugs by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Influenza Antiviral Drugs Market Share by Application
Figure 24. Global Influenza Antiviral Drugs Sales Market Share by Application (2019-2024)
Figure 25. Global Influenza Antiviral Drugs Sales Market Share by Application in 2023
Figure 26. Global Influenza Antiviral Drugs Market Share by Application (2019-2024)
Figure 27. Global Influenza Antiviral Drugs Market Share by Application in 2023
Figure 28. Global Influenza Antiviral Drugs Sales Growth Rate by Application (2019-2024)
Figure 29. Global Influenza Antiviral Drugs Sales Market Share by Region (2019-2024)
Figure 30. North America Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Influenza Antiviral Drugs Sales Market Share by Country in 2023
Figure 32. U.S. Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Influenza Antiviral Drugs Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Influenza Antiviral Drugs Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Influenza Antiviral Drugs Sales Market Share by Country in 2023
Figure 37. Germany Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Influenza Antiviral Drugs Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Influenza Antiviral Drugs Sales Market Share by Region in 2023
Figure 44. China Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Influenza Antiviral Drugs Sales and Growth Rate (K Units)
Figure 50. South America Influenza Antiviral Drugs Sales Market Share by Country in 2023
Figure 51. Brazil Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Influenza Antiviral Drugs Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Influenza Antiviral Drugs Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Influenza Antiviral Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Influenza Antiviral Drugs Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Influenza Antiviral Drugs Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Influenza Antiviral Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Influenza Antiviral Drugs Market Share Forecast by Type (2025-2030)
Figure 65. Global Influenza Antiviral Drugs Sales Forecast by Application (2025-2030)
Figure 66. Global Influenza Antiviral Drugs Market Share Forecast by Application (2025-2030)
